Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African American Patients with Type 2 Diabetes? A Meta-analysis

被引：0
|
作者：
Mishriky, Basem M.
Powell, James R.
Wittwer, Jennifer A.
Chu, Jennifer X.
Sewell, Kerry
Wu, Qiang
Cummings, Doyle M.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-242-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparing Cardiovascular Benefits between GLP-1RA and SGLT2i as an Add-On to Metformin among US Adults with Type 2 Diabetes (T2D)
    Deremer, Christina E.
    Guo, Jingchuan
    Vouri, Scott M.
    Haller, Michael J.
    Donahoo, William T.
    Winterstein, Almut G.
    Shao, Hui
    DIABETES, 2021, 70
  • [22] The impact of ethnicity on efficacy of DPP4I, SGLT2I and GLP-1RA: A systematic review and meta-analysis of randomised controlled trials
    Gan, S.
    Dawed, A. Y.
    Donnelly, L.
    Nair, A. T. N.
    Mohan, V.
    Pearson, E. R.
    DIABETIC MEDICINE, 2020, 37 : 178 - 179
  • [23] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [24] PROVIDER-REPORTED BARRIERS TO GUIDELINE-DIRECTED UTILIZATION OF SGLT2I/GLP-1RA AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK FOR CARDIOVASCULAR DISEASE
    Qian, Frank
    Chaudhary, Richard
    Jonas, Zachary
    Ward, Charlotte
    Moran, Sara
    Quadir, Juweria
    Chen, Zsu-Zsu
    Benson, Mark D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1887 - 1887
  • [25] Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
    Mishriky, B. M.
    Okunrintemi, V
    Jain, S.
    Sewell, K. A.
    Powell, J. R.
    Cummings, D. M.
    DIABETES & METABOLISM, 2021, 47 (01)
  • [26] Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction Call for Action to the Cardiology Community
    Nelson, Adam J.
    Pagidipati, Neha J.
    Aroda, Vanita R.
    Cavender, Matthew A.
    Green, Jennifer B.
    Lopes, Renato D.
    Al-Khalidi, Hussein
    Gaynor, Tanya
    Kaltenbach, Lisa A.
    Kirk, Julienne K.
    Lingvay, Ildiko
    Magwire, Melissa L.
    O'Brien, Emily C.
    Pak, Jonathan
    Pop-Busui, Rodica
    Richardson, Caroline R.
    Reed, Monica
    Senyucel, Cagri
    Webb, Laura
    McGuire, Darren K.
    Granger, Christopher B.
    CIRCULATION, 2021, 144 (01) : 74 - 84
  • [27] Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
    Bea, Sungho
    Jeong, Han Eol
    Filion, Kristian B.
    Yu, Oriana H. Y.
    Cho, Young Min
    Lee, Bon Hyang
    Chang, Yoosoo
    Byrne, Christopher D.
    Shin, Ju-Young
    JAMA NETWORK OPEN, 2023, 6 (12) : E2349856
  • [28] Trends in GLP1RA and SGLT2i Use in Ischemic Stroke Patients With Diabetes
    Yanus, Matthew R.
    Saleni, Angela
    Bhavsar, Riya
    Zhang, Tony
    McCane, Charles D.
    Pan, Alan P.
    Vahidy, Farhaan
    Gadhia, Rajan R.
    STROKE, 2024, 55
  • [29] Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Agarwal, Shubham
    Basit, Mujeeb A.
    Bowen, Michael E.
    Heitjan, Daniel
    Mai, Christine
    Marble, Kelsea
    Xiang, Zichang
    Lingvay, Ildiko
    DIABETES, 2024, 73
  • [30] Sociodemographic disparities in GLP-1RA and SGLT2i use among US adults with type 2 diabetes: NHANES 2005-March 2020
    Mittman, Benjamin G.
    Le, Phuc
    Payne, Julia Y.
    Ayers, Gina
    Rothberg, Michael B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (03) : 377 - 383
12345